DOCSLIB.ORG

Current State of Cardiac Troponin Testing in Duchenne

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Current State of Cardiac Troponin Testing in Duchenne Open access Heart failure and cardiomyopathies Open Heart: first published as 10.1136/openhrt-2021-001592 on 24 March 2021. Downloaded from Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel Christopher F Spurney ,1 Deborah Ascheim,2 Lawrence Charnas ,3 Linda Cripe,4 Kan Hor,4 Nicholas King,5 Kathi Kinnett,6 Elizabeth M McNally,7 John- Michael Sauer,5 Lee Sweeney,8 Chet Villa,9 Larry W Markham10 To cite: Spurney CF, Ascheim D, ABSTRACT failure, myocarditis and cardiomyopathies. Charnas L, et al. Current state of Cardiac disease is now the leading cause of death in Some systemic illnesses are also associated cardiac troponin testing in Duchenne muscular dystrophy (DMD). Clinical evaluations Duchenne muscular dystrophy with troponin release, including pulmonary over time have demonstrated asymptomatic cardiac cardiomyopathy: review and embolism, chronic kidney disease, sepsis and recommendations from the troponin elevations and acute elevations are associated cardiotoxic agents. Troponin release can be Parent Project Muscular with symptoms and cardiac dysfunction in DMD. Clinicians acute or chronic and related to multisystem require a better understanding of the relationship of Dystrophy expert panel. Open involvement.2 3 2021;8:e001592. symptoms, troponin levels and progression of cardiac Heart Cardiomyopathy has become the leading doi:10.1136/ disease in DMD. As clinical trials begin to assess novel openhrt-2021-001592 cause of death in Duchenne muscular cardiac therapeutics in DMD, troponin levels in DMD are 4 important for safety monitoring and outcome measures. dystrophy (DMD). In DMD, case studies of The Parent Project Muscular Dystrophy convened an acute- onset myocardial injury measured by Received 20 January 2021 http://openheart.bmj.com/ expert panel of cardiologists, scientists, and regulatory troponin release are well documented dating Revised 17 February 2021 Accepted 5 March 2021 and industry specialists on 16 December 2019 in Silver back to the 1960s, including a boy 10 years Spring, Maryland and reviewed published and unpublished of age.5 6 More recently, Hor et al7 described data from their institutions. The panel recommended additional cases of acutely elevated troponin retrospective troponin data analyses, prospective levels in subjects with DMD. Elevated troponin longitudinal troponin collection using high-sensitivity levels have been described in asymptomatic cardiac troponin I assays, inclusion of troponin in future patients with DMD long before the devel- clinical trial outcomes and future development of clinical opment of the typical well-defined cardiac guidelines for monitoring and treating troponin elevations 8 in DMD. disease known to associate with DMD. on September 23, 2021 by guest. Protected copyright. Despite these historical reports, troponin elevations in patients with DMD are poorly understood and have unclear significance. INTRODUCTION With the support of the Parent Project Cardiac troponin I (cTnI) and T (cTnT) Muscular Dystrophy (PPMD), a panel of are components of the contractile apparatus experts in neuromuscular disease, adult and of myocardial cells expressed almost exclu- paediatric cardiology, Food and Drug Admin- istration and industry convened to discuss the © Author(s) (or their sively in the heart and are the preferred employer(s)) 2021. Re- use biomarkers for the evaluation of myocardial role of troponin in DMD clinical care and its permitted under CC BY- NC. No injury.1 Other biomarkers including creatine use both as a safety and efficacy biomarker in commercial re- use. See rights DMD clinical trials. and permissions. Published kinase MB (CK- MB) isoform are less sensi- by BMJ. tive and less specific, especially with associ- 2 For numbered affiliations see ated skeletal muscle disease. Various causes TROPONIN AND NEUROMUSCULAR DISEASES end of article. lead to cardiac troponin release, including As noted, cardiac troponin elevations have myocardial ischaemia often related to ather- been described in DMD since the 1960s. Correspondence to Dr Christopher F Spurney; osclerotic coronary obstruction. Other However, cTnT is considered less specific for cspurney@ childrensnational. org non- ischaemic cardiac causes include heart myocardial injury as it is elevated in multiple Spurney CF, et al. Open Heart 2021;8:e001592. doi:10.1136/openhrt-2021-001592 1 Open Heart Open Heart: first published as 10.1136/openhrt-2021-001592 on 24 March 2021. Downloaded from neuromuscular disease conditions, likely reflecting The dystrophin- deficient golden retriever muscular a skeletal muscle source.9 10 Chronic skeletal muscle dystrophy (GRMD) large animal model recapitulates disease can represent a potential cause of cTnT eleva- some aspects of the human cardiomyopathy course tion, particularly when high- sensitivity (hs- cTnT) assay is better than the mdx model. Townsend et al32 adminis- used.11 12 cTnT was demonstrated to correlate better with tered a chronic infusion of a membrane-sealing agent creatine kinase and myoglobin levels than with cTnI, and to severely affected GRMD dogs and found decreased assays showed cross- reactivity of cTnT antibodies with troponin I levels and reduced myocardial fibrosis. A case skeletal muscle TnT. These factors limit the use of cTnT report by Schneider et al33 described a GRMD dog exhib- and CK- MB for assessment of myocardial injury in DMD iting acute cardiac disease including tachyarrhythmia as cTnI is more specific.13 cTnI is not expressed in human associated with significant increase in troponin I, NT-pro- skeletal muscle during development or during regenera- brain natriuretic peptide and progression over a 3- year 14 tive muscle disease processes such as seen in DMD. period to severe dilated cardiomyopathy. In ongoing The clinical significance of elevated cTnI in DMD experiments, monthly troponin I values obtained from and neuromuscular diseases continues to evolve. A dystrophin- deficient dogs revealed periodic spikes in recent study of 117 patients with DMD, Becker muscular troponin levels and an increase in the number of spikes dystrophy (BMD), DMD/BMD carrier, limb- girdle with age correlated with cardiac involvement. Lower muscular dystrophy (LGMD), facioscapulohumeral troponin levels were obtained in older dogs with loss of dystrophy (FSHD) and myotonic dystrophy (DM) type cardiac mass (Sweeney, unpublished data, 2020). The I found a threefold increased risk of cardiac disease in preclinical data support a role for monitoring troponin subjects with an hs- cTnI level greater than 7.6 ng/L levels during therapeutic trials, but further recommen- (Access High Sensitivity Troponin I Assay, Beckman- dations for preclinical studies were not the focus of the 15 Coulter; normal <2.3 ng/L). In a study of 53 subjects expert panel. with dystrophic myopathies (including DMD, DMD carrier, BMD, LGMD 2A, FSHD), DM types I and II, and Becker/Thomsen myotonias, only three subjects, two with DMD and one with DM, had elevated cTnI levels and CLINICAL DATA ON TROPONIN IN DMD all three had evidence of cardiac disease.13 Other studies Troponin levels are used less clinically in paediatrics due have also demonstrated increases in cTnI levels in DMD to low prevalence of ischaemic cardiac disease. In order and BMD.16–18 However, other studies found normal cTnI to understand the relevance of troponin levels in DMD, it levels in DMD.19–21 Elevated cTnT and cTnI levels were is important to determine troponin levels in healthy chil- also detected in DMD/BMD carriers who are at risk of dren. In 2009, the CALIPER (Canadian Laboratory Initi- 22–24 ative on Pediatric Reference Intervals) study of healthy developing cardiomyopathy later in life. hs- cTnI http://openheart.bmj.com/ levels in DM type I were highly elevated in ambulatory children and adolescents published reference laboratory values for paediatric subjects including cTnI using the subjects and predictive of cardiac dysfunction (Architect 34 Stat Troponin Assay, Abbott).25 Elevated cTnI levels were Abbott Architect ci8200. cTnI levels had maximal meas- observed in patients with Friedreich’s ataxia.26 Elevated ures of 0.176 µg/L in subjects less than 1 year old, 0.112 troponin levels also occur in patients with spinal muscular µg/L in subjects 1–5 years old, 0.018 µg/L in subjects atrophy (SMA), and transient increases in cTnI levels (up 6–10 years old, 0.663 µg/L in subjects 11–14 years old, to 0.176 µg/L; assay and normal limit not reported) of and 0.401 µg/L in subjects 15–20 years old. Due to these 35 unclear significance were observed following Zolgensma low levels in normal paediatric patients, Caselli et al infusion in clinical trials. This is an example of uncer- used hs- cTnI testing (Architect Stat High-Sensitivity TnI, on September 23, 2021 by guest. Protected copyright. tainty regarding whether troponin levels are related to Architect i1000SR platform, Abbott Diagnostics) and SMA or whether these reflect the clinical intervention.27 found approximately 13% of all subjects aged <1 month to <18 years had non-detectable levels. hs-cTnI levels were highest in the first month of life (mean 37.5 ng/L) and PRECLINICAL DATA ON TROPONIN IN DYSTROPHIN-DEFICIENT decreased with age (infants: mean 19.4 ng/L; children ANIMAL MODELS 1–10 years: mean 6.5 ng/L; adolescents: mean 3.1 ng/L). Troponin serum levels were assessed in animal models of Males showed significantly higher hs- cTnI levels than dystrophin
Load more

Recommended publications
  • Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy
    International Journal of Molecular Sciences Review Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy Aoife Gowran 1,*, Maura Brioschi 2, Davide Rovina 1 , Mattia Chiesa 3,4 , Luca Piacentini 3,* , Sara Mallia 1, Cristina Banfi 2,* , Giulio Pompilio 1,5,6,* and Rosaria Santoro 1,4 1 Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy; [email protected] (D.R.); [email protected] (S.M.); [email protected] (R.S.) 2 Unit of Cardiovascular Proteomics, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy; [email protected] 3 Bioinformatics and Artificial Intelligence Facility, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy; [email protected] 4 Department of Electronics, Information and Biomedical Engineering, Politecnico di Milano, 20133 Milan, Italy 5 Department of Cardiac Surgery, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy 6 Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy * Correspondence: [email protected] (A.G.); [email protected] (L.P.); cristina.banfi@cardiologicomonzino.it (C.B.); [email protected] (G.P.) Abstract: Despite major progress in treating skeletal muscle disease associated with dystrophinopathies, cardiomyopathy is emerging as a major cause of death in people carrying dystrophin gene mutations that remain without a targeted cure even with new treatment directions and advances in modelling Citation: Gowran, A.; Brioschi, M.; abilities. The reasons for the stunted progress in ameliorating dystrophin-associated cardiomyopathy Rovina, D.; Chiesa, M.; Piacentini, L.; (DAC) can be explained by the difficulties in detecting pathophysiological mechanisms which can also Mallia, S.; Banfi, C.; Pompilio, G.; Santoro, R.
    [Show full text]
  • Disrupted Mechanobiology Links the Molecular and Cellular Phenotypes
    bioRxiv preprint doi: https://doi.org/10.1101/555391; this version posted February 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Disrupted Mechanobiology Links the Molecular and Cellular 2 Phenotypes in Familial Dilated Cardiomyopathy 3 4 Sarah R. Clippinger1,2, Paige E. Cloonan1,2, Lina Greenberg1, Melanie Ernst1, W. Tom 5 Stump1, Michael J. Greenberg1,* 6 7 1 Department of Biochemistry and Molecular Biophysics, Washington University School 8 of Medicine, St. Louis, MO, 63110, USA 9 10 2 These authors contributed equally to this work 11 12 *Corresponding author: 13 Michael J. Greenberg 14 Department of Biochemistry and Molecular Biophysics 15 Washington University School of Medicine 16 660 S. Euclid Ave., Campus Box 8231 17 St. Louis, MO 63110 18 Phone: (314) 362-8670 19 Email: [email protected] 20 21 22 Running title: A DCM mutation disrupts mechanosensing 23 24 25 Keywords: Mechanosensing, stem cell derived cardiomyocytes, muscle regulation, 26 troponin, myosin, traction force microscopy 1 bioRxiv preprint doi: https://doi.org/10.1101/555391; this version posted February 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 27 Abstract 28 Familial dilated cardiomyopathy (DCM) is a leading cause of sudden cardiac death and a 29 major indicator for heart transplant. The disease is frequently caused by mutations of 30 sarcomeric proteins; however, it is not well understood how these molecular mutations 31 lead to alterations in cellular organization and contractility.
    [Show full text]
  • Molecular Genetic Analysis of the Adenomatous Polyposis Coli (APC)
    Molecular Genetic Analysis of the Adenomatous Polyposis Coli(APC) gene region by Garret Malcolm Hampton A thesis submitted in requirement for the degree of Doctor of Philosophy at the University of London May, 1992 Cancer Genetics Laboratory (formerly Director's Laboratory) Imperial Cancer Research Fund London and Department of Genetics and Biometry University College London London University Page -1- ProQuest Number: 10609182 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10609182 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 To my parents and my wife, Kate Page -2- Abstract Familial Adenomatous Polyposis (FAP) is a rare, autosomal dominant predisposition to colorectal cancer, affecting about one in ten thousand individuals in all populations studied. The gene responsible for this syndrome, designated APC (for Adenomatous Polyposis Coli) was mapped to 5q21-q22 by linkage analysis following a cytogenetic report of a male patient with polyposis and an interstitial deletion on 5q. The high incidence of allele loss at 5q21-q22 in carcinomas of sporadic patients suggests that mutation of the APC gene is a very frequent step in the tumorigenic pathway to nonfamilial colorectal carcinomas and emphasises the importance of isolating the gene and identifying its function.
    [Show full text]
  • Profiling of the Muscle-Specific Dystroglycan Interactome Reveals the Role of Hippo Signaling in Muscular Dystrophy and Age-Dependent Muscle Atrophy Andriy S
    Yatsenko et al. BMC Medicine (2020) 18:8 https://doi.org/10.1186/s12916-019-1478-3 RESEARCH ARTICLE Open Access Profiling of the muscle-specific dystroglycan interactome reveals the role of Hippo signaling in muscular dystrophy and age-dependent muscle atrophy Andriy S. Yatsenko1†, Mariya M. Kucherenko2,3,4†, Yuanbin Xie2,5†, Dina Aweida6, Henning Urlaub7,8, Renate J. Scheibe1, Shenhav Cohen6 and Halyna R. Shcherbata1,2* Abstract Background: Dystroglycanopathies are a group of inherited disorders characterized by vast clinical and genetic heterogeneity and caused by abnormal functioning of the ECM receptor dystroglycan (Dg). Remarkably, among many cases of diagnosed dystroglycanopathies, only a small fraction can be linked directly to mutations in Dg or its regulatory enzymes, implying the involvement of other, not-yet-characterized, Dg-regulating factors. To advance disease diagnostics and develop new treatment strategies, new approaches to find dystroglycanopathy-related factors should be considered. The Dg complex is highly evolutionarily conserved; therefore, model genetic organisms provide excellent systems to address this challenge. In particular, Drosophila is amenable to experiments not feasible in any other system, allowing original insights about the functional interactors of the Dg complex. Methods: To identify new players contributing to dystroglycanopathies, we used Drosophila as a genetic muscular dystrophy model. Using mass spectrometry, we searched for muscle-specific Dg interactors. Next, in silico analyses allowed us to determine their association with diseases and pathological conditions in humans. Using immunohistochemical, biochemical, and genetic interaction approaches followed by the detailed analysis of the muscle tissue architecture, we verified Dg interaction with some of the discovered factors.
    [Show full text]
  • Illuminating the Divergent Role of Filamin C Mutations in Human Cardiomyopathy
    Journal of Clinical Medicine Review Cardiac Filaminopathies: Illuminating the Divergent Role of Filamin C Mutations in Human Cardiomyopathy Matthias Eden 1,2 and Norbert Frey 1,2,* 1 Department of Internal Medicine III, University of Heidelberg, 69120 Heidelberg, Germany; [email protected] 2 German Centre for Cardiovascular Research, Partner Site Heidelberg, 69120 Heidelberg, Germany * Correspondence: [email protected] Abstract: Over the past decades, there has been tremendous progress in understanding genetic alterations that can result in different phenotypes of human cardiomyopathies. More than a thousand mutations in various genes have been identified, indicating that distinct genetic alterations, or combi- nations of genetic alterations, can cause either hypertrophic (HCM), dilated (DCM), restrictive (RCM), or arrhythmogenic cardiomyopathies (ARVC). Translation of these results from “bench to bedside” can potentially group affected patients according to their molecular etiology and identify subclinical individuals at high risk for developing cardiomyopathy or patients with overt phenotypes at high risk for cardiac deterioration or sudden cardiac death. These advances provide not only mechanistic insights into the earliest manifestations of cardiomyopathy, but such efforts also hold the promise that mutation-specific pathophysiology might result in novel “personalized” therapeutic possibilities. Recently, the FLNC gene encoding the sarcomeric protein filamin C has gained special interest since FLNC mutations were found in several distinct and possibly overlapping cardiomyopathy phenotypes. Specifically, mutations in FLNC were initially only linked to myofibrillar myopathy (MFM), but are now increasingly found in various forms of human cardiomyopathy. FLNC thereby Citation: Eden, M.; Frey, N. Cardiac represents another example for the complex genetic and phenotypic continuum of these diseases.
    [Show full text]
  • Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular
    JACC: BASIC TO TRANSLATIONAL SCIENCE VOL.4,NO.7,2019 ª 2019 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/). PRECLINICAL RESEARCH Gene Therapy Rescues Cardiac DysfunctioninDuchenneMuscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate a b c d,e Stephen C. Kolwicz, JR,PHD, John K. Hall, PHD, Farid Moussavi-Harami, MD, Xiolan Chen, PHD, d,e b,d,e e,f,g, b,e,g, Stephen D. Hauschka, PHD, Jeffrey S. Chamberlain, PHD, Michael Regnier, PHD, * Guy L. Odom, PHD * VISUAL ABSTRACT Kolwicz, S.C. Jr. et al. J Am Coll Cardiol Basic Trans Science. 2019;4(7):778–91. HIGHLIGHTS rAAV vectors increase cardiac-specific expression of RNR and elevate cardiomyocyte 2-dATP levels. Elevated myocardial RNR and subsequent increase in 2-dATP rescues the performance of failing myocardium, an effect that persists long term. ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2019.06.006 JACC: BASIC TO TRANSLATIONAL SCIENCE VOL. 4, NO. 7, 2019 Kolwicz, Jr., et al. 779 NOVEMBER 2019:778– 91 Nucleotide-Based Cardiac Gene Therapy Restores Function in dmd Mice We show the ability to increase both cardiac baseline function and high workload contractile performance in ABBREVIATIONS aged (22- to 24-month old) mdx4cv mice, by high-level muscle-specific expression of either microdystrophin AND ACRONYMS or RNR. mDys = microdystrophin Five months post-treatment, mice systemically injected with rAAV6 vector carrying a striated muscle-specific CK8 regulatory cassette driving expression of microdystrophin in both skeletal and cardiac muscle, exhibited the = miniaturized murine creatine kinase regulatory greatest effect on systolic function.
    [Show full text]
  • Impacts of Dystrophin and Utrophin Domains on Actin Structural Dynamics: Implications for Therapeutic Design
    doi:10.1016/j.jmb.2012.04.005 J. Mol. Biol. (2012) 420,87–98 Contents lists available at www.sciencedirect.com Journal of Molecular Biology journal homepage: http://ees.elsevier.com.jmb Impacts of Dystrophin and Utrophin Domains on Actin Structural Dynamics: Implications for Therapeutic Design Ava Yun Lin, Ewa Prochniewicz, Davin M. Henderson, Bin Li, James M. Ervasti and David D. Thomas⁎ Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 6-155 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA Received 27 January 2012; We have used time-resolved phosphorescence anisotropy (TPA) of actin received in revised form to evaluate domains of dystrophin and utrophin, with implications for 26 March 2012; gene therapy in muscular dystrophy. Dystrophin and its homolog accepted 2 April 2012 utrophin bind to cytoskeletal actin to form mechanical linkages that Available online prevent muscular damage. Because these proteins are too large for most 11 April 2012 gene therapy vectors, much effort is currently devoted to smaller constructs. We previously used TPA to show that both dystrophin and Edited by R. Craig utrophin have a paradoxical effect on actin rotational dynamics— restricting amplitude while increasing rate, thus increasing resilience, Keywords: with utrophin more effective than dystrophin. Here, we have evaluated time-resolved individual domains of these proteins. We found that a “mini-dystrophin,” phosphorescence anisotropy; lacking one of the two actin-binding domains, is less effective than TPA; dystrophin in regulating actin dynamics, correlating with its moderate muscular dystrophy; effectiveness in rescuing the dystrophic phenotype in mice. In contrast, gene therapy we found that a “micro-utrophin,” with more extensive internal deletions, is as effective as full-length dystrophin in the regulation of actin dynamics.
    [Show full text]
  • Myod Converts Primary Dermal Fibroblasts, Chondroblasts, Smooth
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 7988-7992, October 1990 Developmental Biology MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes (myogenesis/myoflbrils/desmin/master switch genes) J. CHOI*, M. L. COSTAtt, C. S. MERMELSTEINtt, C. CHAGASt, S. HOLTZERt, AND H. HOLTZERt§ Departments of *Biochemistry and tAnatomy, University of Pennsylvania, Philadelphia, PA 19104; and tinstituto de Bioffsica Carlos Chagas Filho, Bloco G, Centro de Ciencias da Sadde, Universidade Federal do Rio de Janeiro, lbha do Funddo, 21941 Rio de Janeiro, Brazil Communicated by Harold Weintraub, June 29, 1990 (received for review June 15, 1990) ABSTRACT Shortly after their birth, postmitotic mono- L6, L8, L6E9, BC3H1, and other types of immortalized nucleated myoblasts in myotomes, limb buds, and conventional and/or mutagenized myogenic lines are induced to differen- muscle cultures elongate and assemble a cohort of myofibrillar tiate (9-13). proteins into definitively striated myofibrils. MyoD induces a MyoD induces a number of immortalized and/or trans- number of immortalized and/or transformed nonmuscle cells formed cell lines to express several myofibrillar genes and to to express desmin and several myofibrillar proteins and to fuse fuse into multinucleated myosacs (14-16). Other transformed into myosacs. We now report that MyoD converts normal lines such as kidney epithelial cells, HeLa cells, and some dermal fibroblasts, chondroblasts, gizzard smooth muscle, and hepatoma lines resist conversion. Judging from the published pigmented retinal epithelial cells into elongated postmitotic micrographs, MyoD-converted nonmuscle cells, like most mononucleated striated myoblasts. The sarcomeric localization myogenic cell lines, do not express the terminal myogenic of antibodies to desmin, a-actinin, titin, troponin-I, a-actin, program fully.
    [Show full text]
  • Mini-Thin Filaments Regulated by Troponin–Tropomyosin
    Mini-thin filaments regulated by troponin–tropomyosin Huiyu Gong*, Victoria Hatch†, Laith Ali‡, William Lehman†, Roger Craig§, and Larry S. Tobacman‡¶ *Department of Internal Medicine, University of Iowa, Iowa City, IA 52242; †Department of Physiology and Biophysics, Boston University, Boston, MA 02118; §Department of Cell Biology, University of Massachusetts, Worcester, MA 01655; and ‡Departments of Medicine and Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL 60612 Edited by Edward D. Korn, National Institutes of Health, Bethesda, MD, and approved December 9, 2004 (received for review September 29, 2004) Striated muscle thin filaments contain hundreds of actin monomers normal-length thin filaments. They also would make possible and scores of troponins and tropomyosins. To study the coopera- approaches to thin-filament structural analysis. We report here tive mechanism of thin filaments, ‘‘mini-thin filaments’’ were the design and purification of mini-thin filaments with the generated by isolating particles nearly matching the minimal intended composition and compare their function to the function structural repeat of thin filaments: a double helix of actin subunits of conventional-length thin filaments. with each strand approximately seven actins long and spanned by Ca2ϩ regulates muscle contraction in the heart and in skeletal a troponin–tropomyosin complex. One end of the particles was muscle by binding to specific site(s) in the NH2 domain of the capped by a gelsolin (segment 1–3)–TnT fusion protein (substitut- troponin subunit, TnC. Significantly, Ca2ϩ activates tension very ing for normal TnT), and the other end was capped by tropomodu- cooperatively (3, 4) even in cardiac muscle, in which each TnC lin.
    [Show full text]
  • Diagnosis and Cell-Based Therapy for Duchenne Muscular Dystrophy in Humans, Mice, and Zebrafish
    J Hum Genet (2006) 51:397–406 DOI 10.1007/s10038-006-0374-9 MINIREVIEW Louis M. Kunkel Æ Estanislao Bachrach Richard R. Bennett Æ Jeffrey Guyon Æ Leta Steffen Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish Received: 3 January 2006 / Accepted: 4 January 2006 / Published online: 1 April 2006 Ó The Japan Society of Human Genetics and Springer-Verlag 2006 Abstract The muscular dystrophies are a heterogeneous mutants carries a stop codon mutation in dystrophin, group of genetically caused muscle degenerative disor- and we have recently identified another carrying a ders. The Kunkel laboratory has had a longstanding mutation in titin. We are currently positionally cloning research program into the pathogenesis and treatment of the disease-causative mutation in the remaining 12 mu- these diseases. Starting with our identification of dys- tant strains. We hope that one of these new mutant trophin as the defective protein in Duchenne muscular strains of fish will have a mutation in a gene not previ- dystrophy (DMD), we have continued our work on ously implicated in human muscular dystrophy. This normal dystrophin function and how it is altered in gene would become a candidate gene to be analyzed in muscular dystrophy. Our work has led to the identifi- patients which do not carry a mutation in any of the cation of the defective genes in three forms of limb girdle known dystrophy-associated genes. By studying both muscular dystrophy (LGMD) and a better understand- disease pathology and investigating potential therapies, ing of how muscle degenerates in many of the different we hope to make a positive difference in the lives of dystrophies.
    [Show full text]
  • Review Increasing Complexity of the Dystrophin-Associated Protein Complex Jonathon M
    Proc. Nadl. Acad. Sci. USA Vol. 91, pp. 8307-8313, August 1994 Review Increasing complexity of the dystrophin-associated protein complex Jonathon M. Tinsley, Derek J. Blake, Richard A. Zuellig, and Kay E. Davies Molecular Genetics Group, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom ABSTRACT Duchenne muscular dys- Purkinje neurons. Alternatively spliced dystrophin-1 (Dp7l) and apo-dystro- trophy is a severe X chromosome-linked, isoforms originating from the carboxyl- phin-3 are regulated by a promoter situ- muscle-wasting disease caused by lack of terminal coding region ofdystrophin have ated between exons 62 and 63 of the the protein dystrophin. The exact function also been described. The significance of dystrophin gene and are expressed in of dystrophin rem to be determined. these isoforms at the RNA and protein nonmuscle tissues, including brain, lung, However, analysis of its interaction with a level has not been elucidated. liver, and kidney. Apo-dystrophin-1 tran- large oligomeric protein complex at the Dystrophin is a 427-kDa protein local- scripts are only detectable in fetal and sarcolemma and the identicaton of a ized to the cytoplasmic face of the sar- newborn muscle. Muscle samples taken structurally related protein, utrophin, is colemma, enriched at myotendinous after 15 days postnatally have no apo- leading to the characterization ofcandidate junctions and the postsynaptic mem- dystrophin-1 transcript as determined by genes for other neuromusular disorders. brane of the neuromuscular junction reverse transcription-PCR. In rat brain, (NMJ). Dystrophin colocalizes with apo-dystrophin-1 transcripts continue in- Duchenne muscular dystrophy (DMD) is f3-spectrin and vinculin in three distinct creasing until they reach a maximum the most common muscular dystrophy, domains at the sarcolemma (overlaying after -1 mo.
    [Show full text]
  • Postmortem Changes in the Myofibrillar and Other Cytoskeletal Proteins in Muscle
    BIOCHEMISTRY - IMPACT ON MEAT TENDERNESS Postmortem Changes in the Myofibrillar and Other C'oskeletal Proteins in Muscle RICHARD M. ROBSON*, ELISABETH HUFF-LONERGAN', FREDERICK C. PARRISH, JR., CHIUNG-YING HO, MARVIN H. STROMER, TED W. HUIATT, ROBERT M. BELLIN and SUZANNE W. SERNETT introduction filaments (titin), and integral Z-line region (a-actinin, Cap Z), as well as proteins of the intermediate filaments (desmin, The cytoskeleton of "typical" vertebrate cells contains paranemin, and synemin), Z-line periphery (filamin) and three protein filament systems, namely the -7-nm diameter costameres underlying the cell membrane (filamin, actin-containing microfilaments, the -1 0-nm diameter in- dystrophin, talin, and vinculin) are listed along with an esti- termediate filaments (IFs), and the -23-nm diameter tubu- mate of their abundance, approximate molecular weights, lin-containing microtubules (Robson, 1989, 1995; Robson and number of subunits per molecule. Because the myofibrils et al., 1991 ).The contractile myofibrils, which are by far the are the overwhelming components of the skeletal muscle cell major components of developed skeletal muscle cells and cytoskeleton, the approximate percentages of the cytoskel- are responsible for most of the desirable qualities of muscle eton listed for the myofibrillar proteins (e.g., myosin, actin, foods (Robson et al., 1981,1984, 1991 1, can be considered tropomyosin, a-actinin, etc.) also would represent their ap- the highly expanded corollary of the microfilament system proximate percentages of total myofibrillar protein. of non-muscle cells. The myofibrils, IFs, cell membrane skel- eton (complex protein-lattice subjacent to the sarcolemma), Some Important Characteristics, Possible and attachment sites connecting these elements will be con- Roles, and Postmortem Changes of Key sidered as comprising the muscle cell cytoskeleton in this Cytoskeletal Proteins review.
    [Show full text]